

Rannakoe J Lehloenya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3008580/publications.pdf>

Version: 2024-02-01

42
papers

1,241
citations

471509

17
h-index

377865

34
g-index

63
all docs

63
docs citations

63
times ranked

1453
citing authors

#	ARTICLE	IF	CITATIONS
1	Recognizing Drug Hypersensitivity in Pigmented Skin. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 219-238.	1.9	6
2	IFN- γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2920-2928.e5.	0.7	6
3	Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 582-584.e1.	3.8	17
4	Pattern and impact of drug-induced liver injury in South African patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and a high burden of HIV. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4483-4485.e1.	3.8	3
5	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2878-2895.e6.	3.8	27
6	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.9	41
7	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	9.4	42
8	The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2019, 155, 1087.	4.1	2
9	Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1653-1655.	3.8	2
10	Treatment can be continued for mild cutaneous reactions associated with efavirenz. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1676-1678.	3.8	7
11	Cost of managing severe cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa. <i>Tropical Medicine and International Health</i> , 2019, 24, 994-1002.	2.3	5
12	Drug hypersensitivity in HIV infection. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 272-282.	2.3	30
13	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	2.9	144
14	Cutaneous Adverse Drug Reactions from Antituberculosis Treatment. , 2019, , 207-215.		0
15	Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Infection. , 2019, , 197-205.		0
16	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	3.8	134
17	Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. <i>Obstetrics and Gynecology</i> , 2018, 131, 739-739.	2.4	0
18	Immune Mechanisms of Drug Allergy. , 2018, , 27-38.		0

#	ARTICLE	IF	CITATIONS
19	Paradoxical worsening of <i>Emergomyces africanus</i> infection in an HIV-infected male on itraconazole and antiretroviral therapy. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006173.	3.0	13
20	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 547-563.	3.8	106
21	AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx186.	0.9	41
22	Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.Â®TB and QFT-GIT). <i>Journal of Thoracic Disease</i> , 2016, 8, 482-489.	1.4	3
23	Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw130.	0.9	14
24	Severe antiretroviralâ€associated skin reactions in South African patients: a case series and caseâ€control analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1313-1319.	1.9	18
25	In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. <i>PLoS Pathogens</i> , 2016, 12, e1005469.	4.7	46
26	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. <i>PLoS ONE</i> , 2015, 10, e0135501.	2.5	13
27	Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2648-2651.	3.0	19
28	Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. <i>Clinical Infectious Diseases</i> , 2015, 61, 1004-1012.	5.8	68
29	Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.. <i>F1000Research</i> , 2015, 4, 175.	1.6	2
30	Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virusâ€infected man. <i>Contact Dermatitis</i> , 2014, 70, 125-127.	1.4	29
31	Incidence of anxiety and depression in a predominantly HIVâ€infected population with severe adverse drug reactions. <i>Clinical and Translational Allergy</i> , 2014, 4, P95.	3.2	2
32	Clinical Presentations of Severe Cutaneous Drug Reactions in HIV-Infected Africans. <i>Dermatologic Clinics</i> , 2014, 32, 227-235.	1.7	13
33	Factors Associated with Increased Mortality in a Predominantly HIV-Infected Population with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. <i>PLoS ONE</i> , 2014, 9, e93543.	2.5	18
34	Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2871-2874.	3.0	27
35	A Dimorphic Fungus Causing Disseminated Infection in South Africa. <i>New England Journal of Medicine</i> , 2013, 369, 1416-1424.	27.0	118
36	Aggressive worsening of SÃzary syndrome during early antiretroviral therapy. <i>Aids</i> , 2013, 27, 1035-1036.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Cutaneous adverse drug reactions caused by FDCAs – we need to characterise and manage them urgently. South African Medical Journal, 2013, 103, 815.	0.6	3
38	Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 2535-2537.	3.0	17
39	590 – A Case of Chronic Urticaria Complicated by Raoultella Ornithinolytica Urinary Tract Infection, Bronchospasm and Angioedema. World Allergy Organization Journal, 2012, 5, S187.	3.5	2
40	Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Review of Anti-Infective Therapy, 2012, 10, 475-486.	4.4	57
41	Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. European Journal of Immunology, 2011, 41, 3253-3260.	2.9	27
42	Dermatologic Manifestations of the Immune Reconstitution Inflammatory Syndrome. Dermatologic Clinics, 2006, 24, 549-570.	1.7	102